Erasca Inc (ERAS) - Total Assets
Based on the latest financial reports, Erasca Inc (ERAS) holds total assets worth $461.23 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net asset quality index of Erasca Inc to measure how much of total assets are equity-financed.
Erasca Inc - Total Assets Trend (2019–2025)
This chart illustrates how Erasca Inc's total assets have evolved over time, based on quarterly financial data. Explore how much of Erasca Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Erasca Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Erasca Inc's total assets of $461.23 Million consist of 72.3% current assets and 27.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.6% |
| Accounts Receivable | $2.50 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Erasca Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Erasca Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Erasca Inc's current assets represent 72.3% of total assets in 2025, a decrease from 92.1% in 2019.
- Cash Position: Cash and equivalents constituted 18.6% of total assets in 2025, down from 53.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Erasca Inc Competitors by Total Assets
Key competitors of Erasca Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Erasca Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.52 | 12.35 | 11.01 |
| Quick Ratio | 9.52 | 12.35 | 11.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $227.12 Million | $289.15 Million | $179.38 Million |
Erasca Inc - Advanced Valuation Insights
This section examines the relationship between Erasca Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.58 |
| Latest Market Cap to Assets Ratio | 10.53 |
| Asset Growth Rate (YoY) | -21.2% |
| Total Assets | $396.15 Million |
| Market Capitalization | $4.17 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Erasca Inc's assets at a significant premium (10.53x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Erasca Inc's assets decreased by 21.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Erasca Inc (2019–2025)
The table below shows the annual total assets of Erasca Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $396.15 Million | -21.17% |
| 2024-12-31 | $502.53 Million | +27.13% |
| 2023-12-31 | $395.30 Million | -23.23% |
| 2022-12-31 | $514.91 Million | +2.69% |
| 2021-12-31 | $501.42 Million | +301.69% |
| 2020-12-31 | $124.83 Million | +124.86% |
| 2019-12-31 | $55.51 Million | -- |
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid … Read more